|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ding L, Zhang Z, Xu Y and Zhang Y:
Comparative study of Her-2, p53, Ki-67 expression and
clinicopathological characteristics of breast cancer in a cohort of
northern China female patients. Bioengineered. 8:383–392. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parsa Y, Mirmalek SA, Kani FE, Aidun A,
Salimi-Tabatabaee SA, Yadollah-Damavandi S, Jangholi E, Parsa T and
Shahverdi E: A review of the clinical implications of breast cancer
biology. Electron Physician. 8:2416–2424. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ali RG, Bellchambers HM and Arkell RM:
Zinc fingers of the cerebellum (Zic): Transcription factors and
co-factors. Int J Biochem Cell Biol. 44:2065–2068. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sankar S, Yellajoshyula D, Zhang B, Teets
B, Rockweiler N and Kroll KL: Gene regulatory networks in neural
cell fate acquisition from genome-wide chromatin association of
Geminin and Zic1. Sci Rep. 6:374122016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhong J, Chen S, Xue M, Du Q, Cai J, Jin
H, Si J and Wang L: ZIC1 modulates cell-cycle distributions and
cell migration through regulation of sonic hedgehog, PI(3)K and
MAPK signaling pathways in gastric cancer. BMC Cancer. 12:2902012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gan L, Chen S, Zhong J, Wang X, Lam EK,
Liu X, Zhang J, Zhou T, Yu J, Si J, et al: ZIC1 is downregulated
through promoter hypermethylation, and functions as a tumor
suppressor gene in colorectal cancer. PLoS One. 6:e169162011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qiang W, Zhao Y, Yang Q, Liu W, Guan H, Lv
S, Ji M, Shi B and Hou P: ZIC1 is a putative tumor suppressor in
thyroid cancer by modulating major signaling pathways and
transcription factor FOXO3a. J Clin Endocrinol Metab.
99:E1163–E1172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang YY, Jiang JX, Ma H, Han J, Sun ZY,
Liu ZM and Xu ZG: Role of ZIC1 methylation in hepatocellular
carcinoma and its clinical significance. Tumour Biol. 35:7429–7433.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma G, Dai W, Sang A, Yang X and Li Q:
Roles of ZIC family genes in human gastric cancer. Int J Mol Med.
38:259–266. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nakakido M, Tamura K, Chung S, Ueda K,
Fujii R, Kiyotani K and Nakamura Y: Phosphatidylinositol glycan
anchor biosynthesis, class X containing complex promotes cancer
cell proliferation through suppression of EHD2 and ZIC1, putative
tumor suppressors. Int J Oncol. 49:868–876. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anticancer drugs. Cancer Res. 58:5315–5320.
1998.PubMed/NCBI
|
|
13
|
Colnaghi R, Connell CM, Barrett RM and
Wheatley SP: Separating the anti-apoptotic and mitotic roles of
survivin. J Biol Chem. 281:33450–33456. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hamy AS, Bieche I, Lehmann-Che J, Scott V,
Bertheau P, Guinebretière JM, Matthieu MC, Sigal-Zafrani B, Tembo
O, Marty M, et al: BIRC5 (survivin): A pejorative prognostic marker
in stage II/III breast cancer with no response to neoadjuvant
chemotherapy. Breast Cancer Res Treat. 159:499–511. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Véquaud E, Desplanques G, Jézéquel P, Juin
P and Barillé-Nion S: Survivin contributes to DNA repair by
homologous recombination in breast cancer cells. Breast Cancer Res
Treat. 155:53–63. 2016. View Article : Google Scholar :
|
|
16
|
Wilson JM, Kunnimalaiyaan S,
Kunnimalaiyaan M and Gamblin TC: Inhibition of the AKT pathway in
cholangiocarcinoma by MK2206 reduces cellular viability via
induction of apoptosis. Cancer Cell Int. 15:132015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jin Q, Feng L, Behrens C, Bekele BN,
Wistuba II, Hong WK and Lee HY: Implication of AMP-activated
protein kinase and Akt-regulated survivin in lung cancer
chemopreventive activities of deguelin. Cancer Res. 67:11630–11639.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Li Q, Liu J, Meng X, Pang R and Li J:
MicroRNA-454 may function as an oncogene via targeting AKT in
triple negative breast cancer. J Biol Res (Thessalon). 24:102017.
View Article : Google Scholar
|
|
20
|
Sauer SJ, Tarpley M, Shah I, Save AV,
Lyerly HK, Patierno SR, Williams KP and Devi GR: Bisphenol A
activates EGFR and ERK promoting proliferation, tumor spheroid
formation and resistance to EGFR pathway inhibition in estrogen
receptor-negative inflammatory breast cancer cells. Carcinogenesis.
38:252–260. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Du G, Cao D and Meng L: miR-21 inhibitor
suppresses cell proliferation and colony formation through
regulating the PTEN/AKT pathway and improves paclitaxel sensitivity
in cervical cancer cells. Mol Med Rep. 15:2713–2719. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ding JH, Yuan LY and Chen GA: Aspirin
enhances the cytotoxic activity of bortezomib against myeloma cells
via suppression of Bcl-2, survivin and phosphorylation of AKT.
Oncol Lett. 13:647–654. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu ZH, Lin C, Liu MM, Zhang J, Tao ZH and
Hu XC: Src inhibition can synergize with gemcitabine and reverse
resistance in triple negative breast cancer cells via the AKT/c-Jun
pathway. PLoS One. 11:e01692302016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Khan Z, Khan AA, Yadav H, Prasad GBKS and
Bisen PS: Survivin, a molecular target for therapeutic
interventions in squamous cell carcinoma. Cell Mol Biol Lett.
22:82017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kawakami H, Tomita M, Matsuda T, Ohta T,
Tanaka Y, Fujii M, Hatano M, Tokuhisa T and Mori N: Transcriptional
activation of survivin through the NF-kappaB pathway by human
T-cell leukemia virus type I tax. Int J Cancer. 115:967–974. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lens SM, Vader G and Medema RH: The case
for survivin as mitotic regulator. Curr Opin Cell Biol. 18:616–622.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu W, Zhu F, Jiang Y, Sun D, Yang B and
Yan H: siRNA targeting survivin inhibits the growth and enhances
the chemosensitivity of hepatocellular carcinoma cells. Oncol Rep.
29:1183–1188. 2013. View Article : Google Scholar
|
|
28
|
Brill E, Gobble R, Angeles C,
Lagos-Quintana M, Crago A, Laxa B, Decarolis P, Zhang L, Antonescu
C, Socci ND, et al: ZIC1 overexpression is oncogenic in
liposarcoma. Cancer Res. 70:6891–6901. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rodríguez-Rodero S, Fernández AF,
Fernández-Morera JL, Castro-Santos P, Bayon GF, Ferrero C,
Urdinguio RG, Gonzalez-Marquez R, Suarez C, Fernández-Vega I, et
al: DNA methylation signatures identify biologically distinct
thyroid cancer subtypes. J Clin Endocrinol Metab. 98:2811–2821.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Verlaat W, Snijders PJ, Novianti PW,
Wilting SM, De Strooper LM, Trooskens G, Vandersmissen J, Van
Criekinge W, Wisman GB, Meijer CJ, et al: Genome-wide DNA
methylation profiling reveals methylation markers associated with
3q gain for detection of cervical pre-cancer and cancer. Clin
Cancer Res. 23:3813–3822. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Du L, Qian X, Dai C, Wang L, Huang D, Wang
S and Shen X: Screening the molecular targets of ovarian cancer
based on bioinformatics analysis. Tumori. 101:384–389. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fang F, Munck J, Tang J, Taverna P, Wang
Y, Miller DF, Pilrose J, Choy G, Azab M, Pawelczak KS, et al: The
novel, small-molecule DNA methylation inhibitor SGI-110 as an
ovarian cancer chemo-sensitizer. Clin Cancer Res. 20:6504–6516.
2014. View Article : Google Scholar : PubMed/NCBI
|
